Publication

Brain cancer propagating cells: biology, genetics and targeted therapies

Downloadable Content

Persistent URL
Last modified
  • 02/20/2025
Type of Material
Authors
    Constantinos G Hadjipanayis, Emory UniversityErwin Van Meir, Emory University
Language
  • English
Date
  • 2009-11
Publisher
  • Elsevier (Cell Press)
Publication Version
Copyright Statement
  • © 2009 Elsevier Ltd. Published by Elsevier Inc. All rights reserved.
License
Final Published Version (URL)
Title of Journal or Parent Work
ISSN
  • 1471-4914
Volume
  • 15
Issue
  • 11
Start Page
  • 519
End Page
  • 530
Grant/Funding Information
  • Our work is supported in part by grants from the NIH (CA86335, CA116804 to EGVM, NS053454 to CGH), American Brain Tumor Association (to CGH), Goldhirsh Foundation (to EGVM), Southeastern Brain Tumor Foundation (to CGH and EGVM), the Brain Tumor Funders Collaborative (to EGVM) and the Georgia Cancer Coalition, Distinguished Cancer Clinicians and Scientists Program (to CGH).
Abstract
  • Cancer propagating cells (CPCs) within primary central nervous system (CNS) tumors (glioblastoma multiforme (GBM), medulloblastoma (MB) and ependymoma) might be integral to tumor development and perpetuation. These cells, also known as brain cancer propagating cells (BCPCs), have the ability to self-renew and proliferate. BCPCs can initiate new tumors in mice with high efficiency and these exhibit many features that are characteristic of patient's brain tumors. Accumulating evidence suggests that BCPCs might originate from the transformation of neural stem cells (NSCs) and their progenitors. Furthermore, recent studies have shown that NSC surface markers also define BCPCs. Ultimately, treatments that include specific targeting of BCPCs might potentially be more effective at treating the entire tumor mass, translating to improved patient survival and quality of life.
Author Notes
Research Categories
  • Biology, Genetics

Tools

Relations

In Collection:

Items